ArticleEndocrine oncology (Bristol, England)2025

Real-world outcomes of lower lenvatinib doses in advanced neuroendocrine tumors: a multinational retrospective study.

G R Almeida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.